13 September 2023 - Has received FDA accelerated approval for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody.

Onco360, the nation’s leading independent specialty pharmacy, will be a pharmacy provider for Elrexfio (elranatamab-bcmm).

Read Onco360 press release